CryoStor® CS10
cGMP-manufactured, animal component-free, defined cryopreservation medium with 10% DMSO
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to º£½ÇÆƽâ°æ Technologies Canada Inc. and its subsidiaries and affiliates (“º£½ÇÆƽâ°æâ€) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
This site is protected by reCAPTCHA and the Ìý²¹²Ô»åÌýÌý²¹±è±è±ô²â.
This site is protected by reCAPTCHA and the Ìý²¹²Ô»åÌýÌý²¹±è±è±ô²â.
Overview
Data Figures
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Resources and Publications
Educational Materials (24)
Publications (114)
An integrated patient-derived colon organoids platform as a functional model for nutraceutical and stress response.
iScience 2026 Jun
Abstract
Nutraceuticals are increasingly investigated for their capacity to modulate oxidative and inflammatory stress, yet preclinical testing still relies largely on immortalized cell lines or animal models that poorly recapitulate human epithelial complexity. To address this gap, we developed an integrated platform based on patient-derived colon organoids generated from non-tumoral mucosa and maintained under proliferative or differentiation conditions to model distinct epithelial states. The system combines millifluidic measurement of individual organoid mass, density, and diameter with bulk RNA sequencing and digital PCR profiling to enable multiparametric characterization. Transcriptional analysis revealed state-specific gene programs and shifts in epithelial and immune-related pathways, while biophysical measurements captured structural remodeling. In this pilot validation, a defined oxidative insult followed by nutraceutical treatment elicited coordinated transcriptional and phenotypic responses. This integrated approach provides a scalable and physiologically relevant framework for functional nutraceutical profiling and mechanistic studies of epithelial stress responses.
Detecting MUNC18-1 related presynaptic dysfunction and rescue in human iPSC-derived neurons
Scientific Reports 2025 Sep
Abstract
Human induced pluripotent stem cell (hiPSC) derived neurons are powerful tools to model disease biology in the drug development space. Here we leveraged a spectrum of neurophysiological tools to characterize iPSC-derived NGN2 neurons. Specifically, we applied these technologies to detect phenotypes associated with presynaptic dysfunction and rescue in NGN2 neurons lacking a synaptic vesicle associated protein MUNC18-1, encoded by syntaxin binding protein 1 gene (STXBP1). STXBP1 homozygous knock out NGN2 neurons lacked miniature post synaptic currents and demonstrated disrupted network bursting as assayed with multielectrode array and calcium imaging. Furthermore, knock out neurons released less glutamate into culture media, consistent with a presynaptic deficit. These synaptic phenotypes were rescued by reconstitution of STXBP1 protein by AAV transduction in a dose-dependent manner. Our results identify a complementary suite of physiological methods suitable to examine the modulation of synaptic transmission in human neurons.
Intra-articular delivery of allogeneic bone marrow derived mesenchymal stromal cells (BM-MSCs) for painful lumbar facet arthropathy: a phase I clinical trial
Stem Cell Research & Therapy 2025 Oct
Abstract
ImportanceLumbar facet arthropathy (LFA) is one of the most common specific disorders associated with low back pain. Current treatments provide only symptomatic relief and are often limited in their long-term effectiveness.Objective To evaluate the safety and preliminary efficacy of intra-articular delivery of allogeneic BM-MSCs in patients with painful LFA.Design, setting, and participantsThis study was a prospective, Phase I, single-arm, open-label clinical trial. Ten patients with painful LFA were enrolled with nine completing the 2-year follow-up.InterventionsAll patients received a single intra-articular administration into two affected lumbar facet joints, with each joint injected 10 million allogeneic BM-MSCs suspended in 1 mL Lactated Ringer’s solution.Main outcomes and measures The primary endpoint was safety, as reflected by adverse events (AEs). Secondary endpoints (and the assessment tools) included low back pain (VAS), physical function (PROMIS CAT Physical Function), health status (PROMIS CATs), and the severity of facet joint degeneration on MRIs. The minimum clinically important difference (MCID) thresholds in this trial were pre-defined as a 50% reduction in low back pain (VAS), or an increase of 2.3 points on the PROMIS CAT Physical Function.ResultsThe procedures were well tolerated. There were no clinical signs of immune reaction to the allogeneic BM-MSCs. No study-related serious AEs were observed. Six patients achieved the MCID on VAS for pain at 6-, 12-, 18-, and 24-month follow-ups and five patients consistently met MCID for the PROMIS CAT Physical Function across all follow-up visits. MRIs showed reduced facet joint degeneration at one or more levels in five patients.Conclusions and relevanceThis study demonstrated a favorable safety profile for intra-articular delivery of BM-MSCs for painful LFA. Preliminary therapeutic benefits were observed, including back pain relief, improved physical function, and reduced facet joint degeneration. Further larger, randomized clinical trials are warranted to further assess its safety and efficacy. Trial Registration ClinicalTrials.gov Identifier: NCT04410731.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13287-025-04674-y.
Related Products
Related Products
Quality Statement:
CRYOSTOR PRODUCTS MEET USP STERILITY AND USP ENDOTOXIN TESTING STANDARDS, AND ARE MANUFACTURED UNDER CGMP.
CRYOSTOR PRODUCTS MEET USP STERILITY AND USP ENDOTOXIN TESTING STANDARDS, AND ARE MANUFACTURED UNDER CGMP.
